CytoReason Cements Proof-of-Concept with Machine-Learning-Facilitated Biomarker Breakthrough in Inflammatory Bowel Disease

April 16, 2018


New Data from CytoReason published in Gut outlines the role of a new technological platform approach that has revealed a new blood-based biomarker that is 94% accurate in pretreatment identification of anti-TNFα non-responders in inflammatory bowel disease (IBD), accounting for approximately 30% of patients, confirming validity of the approach.


The application of this platform led to the identification of the TREM1-CCR2-CCL7 axis (which manages the movement of inflammatory monocytes) and plasma cell abundance as accurate pretreatment markers of anti-TNFα response in inflammatory bowel disease (IBD). The study demonstrated TREM-1 expression in peripheral blood to be an accessible and accurate predictor of non-response. The findings demonstrate the platform’s ability to reconstruct previously lost cellular information and isolate an easier to access blood-based biomarker.

The application of this platform led to the identification of the TREM1-CCR2-CCL7 axis (which manages the movement of inflammatory monocytes) and plasma cell abundance as accurate pretreatment markers of anti-TNFα response in inflammatory bowel disease (IBD). The study demonstrated TREM-1 expression in peripheral blood to be an accessible and accurate predictor of non-response. The findings demonstrate the platform’s ability to reconstruct previously lost cellular information and isolate an easier to access blood-based biomarker.

The data showcases CytoReason’s ability to provide unique immune-system insights and interpretation that generate new directions for enhanced target identification, improved indication assessment, more effective clinical development and advanced real-world evidence strategies that can be embedded in the development process. Identifying blood-based biomarkers for IBD has traditionally been extremely difficult to do. The site of disease is the gut, which is a complex tissue, composed of multiple cell types, whose relation to blood in unclear.

“The overall results were impressive in their clarity and output” said Professor Shai Shen-Orr, PhD., Chief Scientist at CytoReason and Director of the Systems Immunology & Precision Medicine Lab in the Faculty of Medicine at The Technion, Israel Institute of Technology. “We demonstrated our ability to recreate and separate out cellular contributions from bulk tissue measurements, discovering a pretreatment upregulated pathway uniquely in anti-TNFα non-responders. Furthermore, we established a clear biomarker relationship between biopsy and blood, which we were able to validate with high accuracy.”

Tags:

CP Wire

Submit an article to cafepharma's CP Wire. Click here to find out more.

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.